
NT3
Duligo-LC1

图 1



280 nm
HC
LC+2
LC
LC+1
AU
Minutes
360 nm
LC+2
LC+1
AU
Minutes

图 2



Monomer
* VWD1A,Wavelength=280 nm [b]
280 nm
HMWS
10.208
10.602
mAU
Time [min]
* VWD1B,Wavelength=360 nm [b]
360 nm
10.212
10.602
mAU
Time [min]

图 3



*: DXd
SIB001-DXd

图 4



HC+3
280 nm
LC+1
HC+2
AU
Minutes

图 5



VWD1A,Wavelength=280 nm
mAU
Time [min]
9.235
8.394

图 6



: DXd
Patritumab-DXd

图 7



280 nm
HC+3
LC+1
HC+2
AU
0.30
0.20
0.10
0.00
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Minutes

图 8



* VWD1A,Wavelength=280 nm [b]
mAU
160
140
120
100
80
60
40
20
0
9.428
10.156
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Time [min]

图 9



DXd
Duligo-DXd

图 10



280 nm
AU
0.40
0.30
0.20
0.10
0.00
LC+1
HC+2
HC+3
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
45.00
Minutes

图 11



VWD1A,Wavelength=280 nm
mAU
160
140
120
100
80
60
40
20
0
8.532
9.867
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Time [min]

图 12



NT3

图 13



AU
0.40
0.30
0.20
0.10
0.00
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Minutes

图 14



VWD1A,Wavelength=280 nm
mAU
120
100
80
60
40
20
0
9.277
9.923
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Time [min]

图 15



NT3

图 16



AU
0.25
0.20
0.15
0.10
0.05
0.00
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Minutes

图 17



VWD1A,Wavelength=280 nm
mAU
90
80
70
60
50
40
30
20
10
0
9.961
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Time [min]

图 18



DXd

图 19



AU
0.25
0.20
0.15
0.10
0.05
0.00
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00
Minutes

图 20



VWD1A,Wavelength=280 nm
mAU
180
160
140
120
100
80
60
40
20
0
9.101
9.922
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Time [min]

图 21



RP DAR
0
1
2
3
4
0
5
10
15 day
Duligo-LC1-NT3_mouse
Duligo-LC1-NT3_monkey

图 22



MS DAR
0
1
2
3
4
0
5
10
15 day
Duligo-LC1-NT3_mouse
Duligo-LC1-NT3_monkey

图 23



Expression of EGFR & HER3
MFI Fold of Blank
10000
1000
100
10
1
0.1
EGFR
HER3
H1568
H1703
HCC827-HER3
BXPC-3
H322
HCC2279
ASPC1
H2030
H1650
H358
SW480-HER3
A549
HCC38
HCC4006
H1993
GP2D
H441
Calu-3
NUGC4
H508
MCF7
MDA-MB-453
SW620
CHO-HER3

图 24



AsPC1 (Pancreas)
Survival%
120
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10 100
Conc. (nM)
Fab-ZAP + Duligotuzumab
Fab-ZAP + Cetuximab (EGFR)
Fab-ZAP + Patritumab (HER3)
Fab-ZAP

图 25



NUGC4 (Gastric)
Survival%
120
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10 100
Conc. (nM)
Fab-ZAP + Duligotuzumab
Fab-ZAP + Cetuximab (EGFR)
Fab-ZAP + Patritumab (HER3)
Fab-ZAP

图 26



CHO-HER3 (Ovary)
Survival%
120
100
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10 100
Conc. (nM)
Fab-ZAP + Duligotuzumab
Fab-ZAP + Cetuximab (EGFR)
Fab-ZAP + Patritumab (HER3)
Fab-ZAP

图 27




图 28




图 29




图 30




图 31




图 32




图 33




图 34




图 35




图 36




图 37




图 38




图 39



EGFR
Duligo-LC1-NT3
SIB001-Dxd
IgG1LALA
OD450-OD620
Conc. (nM)

图 40



HER3
Duligo-LC1-NT3
SIB001-Dxd
IgG1LALA
OD450-OD620
Conc. (nM)

图 41



Efficacy of EGFR/HER3 ADCs in H508 model
on NUDE mice
h-IgG, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-DXd, 10 mg/kg
ADC dose (i.p)
Tumor volume (mm3)
Days post tumor implantation

图 42



% Body weight change
Body weight change(%)
10
0
-10
-20
-30
30
40
50
60
Days post tumor implantation
h-IgG, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-Dxd, 10 mg/kg

图 43



NUGC4 Model (Gastric Cancer)
Tumor volume (mm3)
1500
1000
500
0
0
5
10
15
20
25
30
35
Days post tumor implantation
**
h-IgG, 10 mg/kg
SIB001-DXd, 10 mg/kg
Patritumab-DXd, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
Duligo-DXd, 10 mg/kg
ADC dose (i.p.)

图 44



Body weight change (%)
Body weight change (%)
20
10
0
-10
-20
10
15
20
25
30
35
Days post tumor implantation
h-IgG, 10 mg/kg
SIB001-DXd, 10 mg/kg
Patritumab-DXd, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
Duligo-DXd, 10 mg/kg

图 45



SW620 Model (Colorectal cancer)
Tumor volume (mm3)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0 5 10 15 20 25 30 35 40 45
Days post tumor implantation
h-IgG, 10 mg/kg
IgG1LALA-NT3 (DAR=4), 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-DXd, 10 mg/kg
ADC dose (i.p.)

图 46



Body weight change (%)
Body weight change (%)
20
10
0
-10
-20
10 15 20 25 30 35 40 45
Days post tumor implantation
h-IgG, 10 mg/kg
IgG1LALA-NT3 (DAR=4), 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-DXd, 10 mg/kg
ADC dose (i.p.)

图 47



AsPC1 Model (Pancreatic Cancer)
Tumor volume (mm3)
800
700
600
500
400
300
200
100
0
0 5 10 15 20 25 30 35
Days post tumor implantation
h-IgG, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-Dxd, 10 mg/kg
ADC dose (i.p.)

图 48



Body weight change (%)
Body weight change (%)
20
10
0
-10
-20
0
5
10
15
20
25
30
Days post tumor implantation
h-IgG, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-Dxd, 10 mg/kg
ADC dose (i.p.)

图 49



H1568 Model (Lung Cancer)
Tumor volume (mm3)
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
35
Days post tumor implantation
h-IgG, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-Dxd, 10 mg/kg
ADC dose (i.p.)

图 50



Body weight change (%)
Body weight change (%)
20
10
0
-10
-20
10
15
20
25
30
35
Days post tumor implantation
h-IgG, 10 mg/kg
Duligo-LC1-NT3, 10 mg/kg
SIB001-Dxd, 10 mg/kg
ADC dose (i.p.)

图 51